Cartherics has an autologous CAR-T product treating ovarian cancer, entering clinical trials in 2024-25. The lead allogeneic product is expected to enter clinical trials for ovarian cancer in 2026. There is a pipeline of additional products focused on solid tumours following close behind. The Cartherics platform is expected to bring significant options for effective therapy across a wide spectrum of cancer types.